Transgene dosed first patient in a Phase 1 Clinical Trial in China
A biotech company that designs and develops virus-based immunotherapies, Transgene confirms dosing the first patient in a Phase 1 Clinical Trial in China, evaluating T101, therapeutic…
Read More...
Read More...